BiomX

BiomX

BiomX was founded in 2015 by a team of scientists from the Weizmann Institute of Science and MIT, with Jonathan Solomon serving as CEO since inception. The company was created to commercialize phage therapy, using naturally occurring viruses that kill specific bacterial strains. In October 2019, BiomX merged with Chardan Healthcare Acquisition Corp., a special-purpose acquisition company, to list on the New York Stock Exchange under the ticker PHGE, raising gross proceeds of roughly $80 million (per the firm's SEC filings, 2019). The firm's pipeline targets bacterial drivers of chronic disease, most notably cystic fibrosis-associated Pseudomonas aeruginosa infections and Cutibacterium acnes in acne vulgaris. BiomX's lead candidate, BX004, entered a Phase 1b/2a clinical trial for CF patients in 2021 in partnership with the Cystic Fibrosis Foundation, which committed $5 million to the program (per the CFF, 2021). A separate dermatology-focused subsidiary, BiomX Aesthetics, was established to develop therapies for acne-prone skin. The company maintains research collaborations in Israel and the United States, combining its proprietary XMarker microbiome-based biomarker platform with phage engineering to select patient populations most likely to respond. As of mid-2024, BiomX operates with a lean publicly reported headcount, having undergone a restructuring in early 2024 to prioritize clinical-stage assets and extend its cash runway. The company completed a merger with Adaptive Phage Therapeutics in March 2024, a stock-for-stock transaction that added APT's pipeline of phage candidates targeting prosthetic joint infections and recurrent urinary tract infections, while APT shareholders received a majority stake in the combined entity (per the firm, March 2024). The Cystic Fibrosis Foundation has remained a recurring development partner, alongside academic institutions in Israel and the U.S. BiomX occupies a narrow structural niche: it is one of fewer than a dozen publicly traded pure-play phage therapy companies globally, a position that gives it access to equity markets but exposes it to the high volatility typical of pre-revenue biotech. The March 2024 merger with APT expanded its addressable indications while consolidating two parallel phage platforms under a single sponsor-supported pipeline — an operational move that differentiates it from academic phage centers still funded primarily by grants.